Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 24.09 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-14
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 21.43K shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 2.66K shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was 0.00 shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-06-30 was 0.00 shares.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 790.86K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 21.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 24.09K shares 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | 2.66K shares 10-Q · filed 2026-05-14 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-03 | 0.00 shares 10-Q · filed 2023-11-03 | 789.36K shares derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 0.00 shares 10-Q · filed 2023-08-08 | 789.36K shares derived: sum of 3 quarters · filed 2023-08-08 | 789.36K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | 789.36K shares derived: sum of 2 quarters · filed 2023-05-09 | 789.36K shares derived: sum of 3 quarters · filed 2023-05-09 | |
| 2022-12-31 | 789.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | 789.36K shares derived: sum of 2 quarters · filed 2023-03-21 | 790.86K shares 10-K · filed 2023-03-21 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.50K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 1.50K shares 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |